Researchers have identified a promising new weapon against triple-negative breast cancer, one of the most aggressive forms of ...

Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinical-stage biotechnology company focused on unlocking new therapeutic ...

Researchers in Switzerland have conducted the first systematic study that demonstrated that even small variations in a person’s genome can disrupt the therapeutic effects of monoclonal antibodies. “We ...

The prevalence of serious inflammatory safety issues such as cytokine release syndrome and immune effector cell–associated ...

More than half of patients in a Phase III clinical trial who received a limited course of the experimental monoclonal ...

According to a Phase I study led by researchers at The University of Texas MD Anderson Cancer Center, published today in Nature Medicine , the novel monoclonal antibody linavonkibart demonstrated the ...

According to a Phase I study led by researchers at The University of Texas MD Anderson Cancer Center, published in Nature Medicine, the novel monoclonal antibody linavonkibart has demonstrated the ...

Among patients with relapsed or refractory multiple myeloma, Tecvayli (teclistamab-cqyv) monotherapy was associated with a 71 ...

America has an Alzheimer’s problem, devastating families and driving soaring healthcare costs. More than 7 million people over 65 years old live with Alzheimer’s dementia today, a number predicted to ...

Novartis NVS announced that the FDA granted Breakthrough Therapy designation to its pipeline candidate, ianalumab for the ...

What price would you pay for the chance of just a little more quality time with a loved one facing declining cognition from ...